12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Intellikine, Takeda deal

Takeda will acquire cancer company Intellikine for $190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128, an inhibitor...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >